Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014  U.S. ... portfolio by signing an exclusive license for technology developed ... to control gene expression in plants, including for applications ... species. The technology was developed under ... science officer at Kultevat and former president of the ...
(Date:9/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... agreement with Merck Animal Health to market Neogen,s Igenity ... Igenity Dairy Heifer Program consists of genomic tests that ... potential of replacement dairy heifers. The genomic tests can ... is an excellent tool in the decision-making process for ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 2
... LABS, Inc., the recognized leader in microbiology, infectious ... the transplant and biomedical sciences communities, today announced ... President of Strategic Development following two years with ... LABS, Inc. client base significantly. In ...
... announced the sale of its leading Sustenex® ... dietary supplements to Schiff Nutrition International, Inc. ... royalties on Schiff products containing GanedenBC30 ™.  The ... probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and dietary ...
... 2011 To aid the fight of the deadly ... and their collaborators at the University Medical Centre Hamburg-Eppendorf ... upon the sequencing data previously released and submitted to ... the first genomes assembled using the latest ion semiconductor ...
Cached Biology Technology:LABS, Inc. Promotes Chad Ronholdt to VP of Strategic Development 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... that as some populations of an organism evolve a ... segment of the lifespan that contributes to "fitness" ?the ... the next generation. , Focusing on guppies, small fresh-water ... that guppies living in environments with a large number ...
... teeth and jawbones of two new species of tiny monkey-like ... from ancient sediments in the Egyptian desert, researchers have reported. ... common ancestor of living anthropoids -- including monkeys, apes and ... already begun branching into many species by that time. Also, ...
... Institute of Allergy and Infectious Diseases (NIAID), part ... how a promising drug candidate attacks the bacterium ... in Proceedings of the National Academy of Sciences, ... candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb). ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Ancient anthropoid origins discovered in Africa 2Ancient anthropoid origins discovered in Africa 3NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... subcloning of gene in baculoviral expression ... and plaque purification of ten clones, ... for one clone, protein expression and ... culture. Expected yield and timeline: 1-4 ...
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Biology Products: